Notizie e Video - GlobeNewsWire - Pagina 4

POMPANO BEACH, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today announced the successful completion of comprehensive audits for fiscal years 2022 and 2023. This completion is a significant step in the company’s strategy to uplist to a senior stock exchange. The primary purpose of this audit was to strategize BioStem's...

VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Torr Metals Inc. (“ Torr” or the " Company ") (TSX-V: TMET.V) is very pleased to announce preliminary results that have identified near-surface high priority geophysical resistivity anomalies extending up to >1.5 kilometers (km) depth that are coincident with highly anomalous copper (Cu), gold (Au), and molybdenum (Mo) mineralization at-surface (Figure 1). These compelling exploration drill targets have been...

KING OF PRUSSIA, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions and a member of Oracle PartnerNetwork (OPN), today announced that it has been selected to join the Oracle Independent Software Vendor (ISV) Accelerator for SaaS Initiative. With expertise in Oracle Cloud Fusion Cloud Applications integrations, Vertex continues to leverage the power of contract and tax data to optimize customer...

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. Details of the oral presentation are as follows: Title: Healthy Donor vs Patient Manufactured Autologous Deltex DRI Product; Immunophenotyping Gene...

FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care,...

Philadelphia, PA, April 24, 2024 (GLOBE NEWSWIRE) -- Automotive Retail Car Dealers can Use the Turnkey DriveItAway App and Software Platform, with Fleet Credit Line Options by Westlake Fleet, part of Westlake Financial , to Provide All Prospects, Regardless of Down Payment or Credit History, the Ability to Choose a Vehicle and “Drive It Away” with a Micro-Lease with Terms Established by the Dealer The DriveItAway Platform Enables Customers Rejected for a Regular Vehicle Purchase Finance or...

SOUTH SAN FRANCISCO, Calif. and MIAMI, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 (NF1) and other indications, today announced the first cohort of 3 patients have commenced dosing. PAS-004 is being evaluated in a Phase 1 multicenter open label clinical trial (...

VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), along with the Centre for Human Drug Research (CHDR), will present its Phase 1 stroke study data at the Interdisciplinary Conference on Psychedelic Research being held June 6-8,...

The Supervisory Board of Aktsiaselts Infortar decided to extend the terms of office of the Member of the Management Board of Aktsiselts Infortar Mrs Eve Pant by 3 years, starting from 17 May 2024. Infortar operates in five countries, the company's main fields of activity are energy, maritime transport, and real estate. Infortar owns a 42,3% stake in AS Tallink Grupp, a 100% stake in AS Eesti Gaas and a versatile and modern real estate portfolio of approx. 110,000 m2. In addition to the three...

Highlights: In Q1 2024, hard rock gold production amounted to 86.3 kg (2,774 oz), compared to 139.0 kg (4,469 oz) in Q1 2023, a decrease of 38%, or 52.7 kg (1,695 oz); Due to the seasonality of the operations at Staroverinskaya (Solcocon), there was no alluvial gold production in Q1; In Q1 2024, total gold sales amounted to 133.2 kg (4,282 oz), compared to 147.9 kg (4,755 oz) in Q1 2023, a decrease of 14.7 kg (473 oz), or 10%; 104,617 tonnes of ore with an average grade of 1.03 g/t were...

The Supervisory Board of Aktsiaselts Infortar approved the audited annual report for 2023 and will submit it to the Annual General Meeting for approval. Major events Energy - The group's electricity and gas sales volumes doubled in 2023, reaching a total of 15.9 TWh in Finland, Estonia, Latvia, Lithuania, and Poland. - The most substantial investment in 2023 was the acquisition of Gaso, which owns the gas distribution network in Latvia. This led to a significant expansion in the infrastructure...

MIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will effect a 1-for-75 reverse split of its issued and outstanding common stock. Avenue expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of...

CARLSBAD, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- AppTech Payments Corp. (Nasdaq: APCX) (“AppTech” or the “Company”), a pioneering Fintech company powering frictionless commerce, announces that Luke D’Angelo, Chief Executive Officer, will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2024. The conference is being held on April 30 – May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV. Presentation Date: May 1, 2024 Time: 1:30pm Pacific Time (Track 1)...

Significant copper and molybdenum intersections include: HM19: 116 m from near surface @ 0.54% CuEq HM20: 26.00 m @ 0.44% CuEq HM24: 44.00 m 0.32% CuEq HM36: 207 m @ 0.49% Cu Eq including 92.00 m @ 0.58% CuEq HM37: 255 m from surface @ 0.36% CuEq including 38.00 m @ 0.45% and 98.00 m @ 0.44% CuEq All drill intercepts included multiple + 2 metre samples with > 1.00% CuEq with one interval returning 3.95% CuEq, the highest in the history of the project VANCOUVER, British Columbia, April 24, 2024...

LOUISVILLE, Ky., April 24, 2024 (GLOBE NEWSWIRE) -- Stock Yards Bancorp, Inc. (NASDAQ: SYBT), parent company of Stock Yards Bank & Trust Company, with offices in Louisville, central, eastern and northern Kentucky, as well as the Indianapolis, Indiana and Cincinnati, Ohio metropolitan markets, today reported earnings of $25.9 million, or $0.88 per diluted share, for the first quarter ended March 31, 2024. This compares to net income of $29.0 million, or $0.99 per diluted share, for the first...

DETROIT, April 24, 2024 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets, today announced the beta release of NurseMagic™, an innovative and proprietary app designed for nurses. This new web app uses AI to provide helpful and easy-to-use tools for over 5.2 million nurses, making their daily tasks easier and more efficient. Additionally, with its status as a Joint...

JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in the Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event to be held in New York City. InflaRx will participate in a panel titled, New Potential Dermatology Treatments for Psoriasis, Urticaria, and Alopecia scheduled on May 14, 2024, at 2:30 PM EDT /...

Octopus AIM VCT plc Net Asset Value Octopus AIM VCT plc announces that as at 22 April 2024 the unaudited net asset value of the Ordinary shares was approximately 63.8 pence per share. For further information, please contact: Rachel Peat Octopus Company Secretarial Services Limited Tel: +44 (0)80 0316 2067 LEI: 213800C5JHJUQLAFP619...

Octopus AIM VCT 2 plc Net Asset Value Octopus AIM VCT 2 plc announces that as at 22 April 2024 the unaudited net asset value of the Ordinary shares was approximately 49.2 pence per share. For further information, please contact: Rachel Peat Octopus Company Secretarial Services Limited Tel: +44 (0)80 0316 2067 LEI: 213800BW27BKJCI35L17...

8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Rathbones Group Plc (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in...